NGM Bio to Host the First of Four Virtual R&D Events on March 30, 2022
NGM Biopharmaceuticals (NGM), a biotech company, will host the first of its four-part Explorer Series virtual R&D events on March 30, 2022. From 11:00 am to 12:15 pm ET, the event will showcase NGM's productive discovery engine, featuring presentations from CEO David Woodhouse and CSO Jin-Long Chen. The series will introduce a preclinical program and subsequent sessions will cover ongoing therapeutic candidates: NGM707, NGM831, NGM438, and NGM621. Live webcasts will be available on NGM's website, with replays archived for a year.
- None.
- None.
--The four-part series titled the “Explorer Series” will showcase NGM Bio’s discovery engine, myeloid reprogramming and checkpoint inhibition portfolio and program for the treatment of geographic atrophy--
SOUTH SAN FRANCISCO, Calif., March 21, 2022 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced it will host the first of four virtual R&D events on Wednesday, March 30, 2022, from 11:00 am – 12:15 pm ET. This four-part series of virtual webcasts, titled the “Explorer Series”, will highlight the company’s work as explorers on the frontier of life-changing science.
The first event will focus on NGM Bio’s highly productive discovery engine which has generated NGM Bio’s entire pipeline of therapeutic candidates. The program will feature presentations from David Woodhouse, Ph.D., Chief Executive Officer and Jin-Long Chen, Ph.D., Founder and Chief Scientific Officer as well as multiple members of NGM Bio’s biology, biologics, and translational teams. During the presentations, NGM Bio will introduce a previously undisclosed preclinical program as a new example of its discovery engine in action.
Future sessions will cover four NGM Bio-discovered programs – NGM707 (a dual ILT2/ILT4 antagonist antibody product candidate), NGM831 (an ILT3 antagonist antibody product candidate), NGM438 (a LAIR1 antagonist antibody product candidate) and NGM621 (an anti- complement C3 antibody product candidate). Each session will feature members from NGM Bio’s management and scientific team as well as leading industry physicians and scientists.
A live webcast of the presentation will be available under the Investors and Media section of NGM Bio’s website at https://ir.ngmbio.com/events-presentations. A replay of the webcast will be archived on NGM Bio’s site for one year following the event.
To register for the event, please visit this link.
About NGM Bio
NGM Bio is focused on discovering and developing novel, life-changing medicines for people whose health and lives have been disrupted by disease. The company’s biology-centric drug discovery approach aims to seamlessly integrate interrogation of complex disease-associated biology and protein engineering expertise to unlock proprietary insights that are leveraged to generate promising product candidates and enable their rapid advancement into proof-of-concept studies. As explorers on the frontier of life-changing science, NGM Bio aspires to operate one of the most productive research and development engines in the biopharmaceutical industry. All therapeutic candidates in the NGM Bio pipeline have been generated by its in-house discovery engine, with a disease-agnostic mindset, always led by biology and motivated by unmet patient need. Today, the company has seven disclosed programs, including four in Phase 2 or 2b studies, across three therapeutic areas: cancer, retinal diseases and liver and metabolic diseases. Visit us at www.ngmbio.com for more information.
Investor Contact: Brian Schoelkopf ir@ngmbio.com | Media Contact: media@ngmbio.com |
FAQ
What is the purpose of NGM's Explorer Series virtual event?
When will the first event of the Explorer Series take place?
Who will present at the first Explorer Series event?
What therapeutic candidates will be covered in the Explorer Series?
How can I watch the NGM Explorer Series event?
